Viridian Therapeutics, Inc.\DE (VRDN) Form 8-K — May 26, 2026
Viridian Therapeutics, Inc. (VRDN) entered into a Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited on May 24, 2026. The agreement secures long-term supply of veligrotug drug substance and product for commercial use, contingent on regulatory approval. The initial term of the agreement is five years, with automatic renewals for successive five-year periods.
Key figures
- Price fixed until
- 2026-12-31
- Agreement term years
- 5
- Renewal period years
- 5
Price after filing
1 day: +1.5%7 days: -6.6%30 days: +1.9%
Close on the filing date to close N calendar days later (from $17.00). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.